GGrantIndex
← Leaderboards

Harold C Smith

University Of Rochester

$6,437,357
Attributed
$6,437,357
Total exposure
8
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1M · FY200517
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17

Funding mix

By agency

NIH$6,437,357 · 8

By mechanism

R01$4,269,380 · 3
R21$2,167,977 · 5

Top collaborators

No co-investigators on record.

Most similar at University Of Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Validation

Research focus

ValidationCellsMutationHigh Throughput ScreeningAntiviral AgentsProteinsMolecular ProbesDoseCytotoxicityViralHost DefenseLifeResponsePublic Health RelevanceHiv InfectionsFutureBaseLeadScaffoldBinding (Molecular Function)PropertyInnovationPreventResistant Strain

Grant awards (21)

Discovery of Chemical Probes for RNA-Binding Protein Host Defense Factors$560,451
R01 · FY2017 · GM · contact PI
Binding Interface of HIV Vif and APOBEC3G as a Therapeutic Target$200,879
R21 · FY2017 · AI · contact PI
Discovery of Chemical Probes for RNA-Binding Protein Host Defense Factors$605,606
R01 · FY2016 · GM · contact PI
Binding Interface of HIV Vif and APOBEC3G as a Therapeutic Target$403,638
R21 · FY2016 · AI · contact PI
Discovery of Chemical Probes for RNA-Binding Protein Host Defense Factors$601,514
R01 · FY2015 · GM · contact PI
Identification of Antagonists of the Molecular Chaperone Function of CBF beta$439,233
R01 · FY2015 · GM · contact PI
Identification of Antagonists of the Molecular Chaperone Function of CBF beta$439,233
R01 · FY2014 · GM · contact PI
Identification of Antagonists of the Molecular Chaperone Function of CBF beta$44,845
R01 · FY2014 · GM · contact PI
Identification of Antagonists of the Molecular Chaperone Function of CBF beta$468,483
R01 · FY2013 · GM · contact PI
Development of a Novel HIV/AIDS Therapeutic Activating the APOBEC3G Host Defense$210,000
R21 · FY2012 · AI · contact PI
Development of a Novel HIV/AIDS Therapeutic Activating the APOBEC3G Host Defense$252,000
R21 · FY2011 · AI · contact PI
Development of a High Throughput Screen for Antagonists of Vif Dimerization$32,250
R21 · FY2011 · NS · contact PI
Development of a High Throughput Screen for Antagonists of Vif Dimerization$128,710
R21 · FY2009 · NS · contact PI
Based deamination by CEM15 suppresses HIV-1 Infectivity$234,000
R21 · FY2005 · AI
The Role of mRNA Editing in B Cell Development$236,250
R21 · FY2004 · AI
Based deamination by CEM15 suppresses HIV-1 Infectivity$234,000
R21 · FY2004 · AI
METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITING$279,125
R01 · FY2003 · DK
Role of mRNA Editing in B Cell Development$236,250
R21 · FY2003 · AI
METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITING$279,125
R01 · FY2002 · DK
METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITING$279,125
R01 · FY2001 · DK
METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITING$272,640
R01 · FY2000 · DK